LIGHT YEAR CAPITAL
Access Institutional-Quality Private Markets
Curated Partnerships. Disciplined Execution. Aligned Capital.
$0M+
Capital Deployed
0+
Investors (27% repeat)
$0M+
Capital Distributed
0+
States Represented
NEW DEAL
CORONA BLADE
Corona Blade | Lamina Surgical
A $5M seed-stage medical device opportunity in a single-use electrosurgical pencil with 5–9× less thermal spread than the Bovie, built to plug into the generators hospitals already own. Backed by a leadership team with 23 prior FDA clearances and $300M+ in surgical-device exits, this SAFE round ($20M cap, 20% discount) targets FDA 510(k) submission in Q4 2027 and a 2030–2031 exit window.
Why Investors Partner with
Light Year Capital
We partner closely with our investors to source, evaluate, and structure private market opportunities across real assets, private credit, and select operating businesses. Our approach is grounded in disciplined selection, true alignment of incentives, and thoughtful risk management—so our investors can participate with clarity and confidence.
Strategic Pipeline | 2026
Investment Portfolio
Strategic Partner Collaborations
Broader strategic partner network investments and curated opportunities